Details for Patent: 11,202,767
✉ Email this page to a colleague
Which drugs does patent 11,202,767 protect, and when does it expire?
Patent 11,202,767 protects OLPRUVA and is included in one NDA.
This patent has twenty-five patent family members in twenty countries.
Summary for Patent: 11,202,767
| Title: | Methods of treating urea cycle disorders and maple syrup urine disease |
| Abstract: | The present invention provides methods for the treatment of urea cycle disorders and Maple Syrup Urine Disease. |
| Inventor(s): | Appel Leah E., Shockey Joshua R., Schelling D. Christopher |
| Assignee: | Acer Therapeutics Inc. |
| Application Number: | US17196599 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 11,202,767
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-001 | Dec 22, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE | ⤷ Sign Up | ||||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-002 | Dec 22, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE | ⤷ Sign Up | ||||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-003 | Dec 22, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE | ⤷ Sign Up | ||||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-004 | Dec 22, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE | ⤷ Sign Up | ||||
| Acer | OLPRUVA | sodium phenylbutyrate | FOR SUSPENSION;ORAL | 214860-005 | Dec 22, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,202,767
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016398029 | ⤷ Sign Up | |||
| Brazil | 112018068665 | ⤷ Sign Up | |||
| Canada | 3017573 | ⤷ Sign Up | |||
| Denmark | 3429559 | ⤷ Sign Up | |||
| European Patent Office | 3429559 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
